EUVIMEDOpdag EUVIMED
Crossref

Unravelling the Mechanism of Cisplatin Resistance in Triple-Negative Breast Cancer: Insights from Metabolomic Profiling via Mass Spectrometry Analysis

Shashwati Parihari, Anvita Pant, Ankit Halder, Sanjeeva Srivastava iD

Journal of the American Society for Mass Spectrometry · 2025

DOI: 10.1021/jasms.4c00445 ↗

At a glance

Journal article in Journal of the American Society for Mass Spectrometry, 2025. Written by Shashwati Parihari and 3 co-authors. Institution: Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay, Mumbai 400076, India. Major MEDLINE topics: Cisplatin, Triple Negative Breast Neoplasms, Drug Resistance, Neoplasm, Metabolomics. Cited 2 times so far (Crossref); 74 references. Funded by: Council of Scientific and Industrial Research, India, Merck, Koita Centre for Digital Health.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Triple-negative breast cancer (TNBC) poses a significant challenge due to its aggressive nature and limited treatment options, with cisplatin often used in treatment. However, the mechanism underlying the cisplatin resistance in TNBC is poorly understood. This study aimed to develop a cisplatin-resistant (cisR) TNBC cell line and understand its metabolic alterations. Characterization of cisR and cisplatin-sensitive (cisS) cell lines involved cytotoxicity, wound healing, and morphological studies. This study further employed untargeted and targeted mass spectrometry analyses for a deep metabolome comparison between cisR and cisS TNBC cell lines to elucidate the molecular mechanisms driving cisplatin resistance. Metabolomics profiling of cisR and cisS cell lines resulted in the identification of significantly altered metabolites, such as N 8-acetylspermidine, d -pantothenic acid, sphingosine, sphinganine 1-phosphate (S1P), nicotinamide, choline, and certain amino acids. This global and targeted metabolomics study also revealed the downregulation of N 8-acetylspermidine and d -pantothenic acid, indicating that their dysregulation is associated with cisplatin resistance in TNBC cells. Furthermore, this study unravels the dysregulation of sphingolipid metabolism, particularly the downregulation of ceramide, sphingosine, and S1P, and glycerophospholipid metabolism (choline, LysoPC) as a potential contributor to cisplatin resistance in TNBC cells. Similarly, upregulation of nicotinamide metabolism key players nicotinate and 1-methylnicotinamide emerges as a contributor to cisplatin resistance. Aminoacyl t-RNA biosynthesis and ABC transporter metabolic pathways involving proline, valine, threonine, glutamic acid, and phenylalanine amino acids are also implicated in developing TNBC-resistant cells. This comprehensive metabolomics study identifies distinct metabolic signatures and key dysregulated pathways associated with cisplatin resistance in TNBC, offering potential candidate marker and therapeutic targets.

Subjects

MeSH terms (MEDLINE)

CisplatinTriple Negative Breast NeoplasmsDrug Resistance, NeoplasmMetabolomicsMetabolomeAntineoplastic AgentsMass SpectrometryHumansCell Line, TumorFemale

Author keywords

Cisplatin resistanceMDA-MB-231Mass spectrometerMetabolomicsTNBCTargeted metabolomicsTriple-negative breast canceruntargeted metabolomics

Substances

CisplatinAntineoplastic Agents

Authors and institutions

  • Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay, Mumbai 400076, India.
  • Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 7610001, Israel.

ORCID profiles: Sanjeeva Srivastava

Funding

  • Council of Scientific and Industrial Research, India
  • Merck
  • Koita Centre for Digital Health

Cite

APA

Parihari, S., Pant, A., Halder, A., & Srivastava, S. (2025). Unravelling the Mechanism of Cisplatin Resistance in Triple-Negative Breast Cancer: Insights from Metabolomic Profiling via Mass Spectrometry Analysis. Journal of the American Society for Mass Spectrometry. https://doi.org/10.1021/jasms.4c00445

Vancouver

Parihari S, Pant A, Halder A, Srivastava S. Unravelling the Mechanism of Cisplatin Resistance in Triple-Negative Breast Cancer: Insights from Metabolomic Profiling via Mass Spectrometry Analysis. Journal of the American Society for Mass Spectrometry. 2025. doi:10.1021/jasms.4c00445

BibTeX
@article{Parihari2025,
  author = {Parihari, Shashwati and Pant, Anvita and Halder, Ankit and Srivastava, Sanjeeva},
  title = {Unravelling the Mechanism of Cisplatin Resistance in Triple-Negative Breast Cancer: Insights from Metabolomic Profiling via Mass Spectrometry Analysis},
  journal = {Journal of the American Society for Mass Spectrometry},
  year = {2025},
  doi = {10.1021/jasms.4c00445}
}
Start for free →